ContributorsPublishersAdvertisers

#Nccn

pharmacytimes.com

Understanding Second-Line Treatment Options for MZL

Bhavesh Shah, RPh, BCOP: We talked about some of the general treatments that we have for these patients. Looking at the NCCN [National Comprehensive Cancer Network] guidelines, which everybody uses, a lot of the treatments have impact on payer coverage. They have impact on level of evidence and practice. I know of institutions that directly take the NCCN guidelines and put them into their electronic medical record. Javier, can you comment on some of the regimens from the NCCN guidelines that are utilized for this disease?
CANCER
Picture for Understanding Second-Line Treatment Options for MZL
targetedonc.com

Part 1: Guidelines and Recommendations for Treating nmCRPC

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the recommended approach to front-line treatment of castration-resistant prostate cancer. During a live virtual event, Eleni Efstathiou, MD, PhD, section chief of Genitourinary Medical Oncology Houston Methodist Oncology Partners, discussed the recommended approach to front-line treatment of castration-resistant prostate cancer.
CANCER
Picture for Part 1: Guidelines and Recommendations for Treating nmCRPC
scienmag.com

PKU Cancer Hospital publishes real-world evidence on Minimally Invasive and Open Esophagectomy

A group led by Prof. Ke Yang of Peking University Cancer Hospital released real-world evidence evaluating outcomes of minimally invasive esophagectomy (MIE) compared with open esophagectomy (OE) in localized esophageal squamous cell carcinoma (ESCC) patients. The study, titled “Minimally Invasive or Open Esophagectomy for Treatment of Resectable Esophageal Squamous Cell Carcinoma? Answer from a Real-World Multicenter Study”, appeared online on November 11 in Annals of Surgery, one of the top journals in the field.
DISEASES & TREATMENTS
Picture for PKU Cancer Hospital publishes real-world evidence on Minimally Invasive and Open Esophagectomy
TRENDING TOPICS
MedicalXpress

Real-world evidence on minimally invasive and open esophagectomy

A group led by Prof. Ke Yang of Peking University Cancer Hospital released real-world evidence evaluating outcomes of minimally invasive esophagectomy (MIE) compared with open esophagectomy (OE) in localized esophageal squamous cell carcinoma (ESCC) patients. The study, titled "Minimally Invasive or Open Esophagectomy for Treatment of Resectable Esophageal Squamous Cell Carcinoma? Answer from a Real-World Multicenter Study," appeared online on November 11 in Annals of Surgery.
SCIENCE
targetedonc.com

Sequencing Therapy With Novel Agents in Metastatic Cholangiocarcinoma

Afsaneh Barzi, MD, PhD: There are good chemotherapy combinations in this patient population. We talked about FOLFOX [folinic acid, fluorouracil, oxaliplatin] based on the ABC-06 trial, and we talked about 5-FU [fluorouracil] and Onivyde [liposomal irinotecan] based on the NIFTY trial. There are targeted therapies for patients we are identifying, and in those who are MSI [microsatellite instability]-high, pembrolizumab remains a recommended second-line therapy in this patient population. Outside of that, although there are some smaller studies and a recommendation by NCCN [National Comprehensive Cancer Network] to consider immunotherapy in subsequent lines of therapy, I would say I don’t have any high-quality data to strongly recommend immunotherapy. I think we have very good chemotherapy options that have shown efficacy in trials and very good targeted therapy options, if you’re thinking about immunotherapy, we should really see trials that are evaluating immunotherapy in second and subsequent lines of therapy. Additionally, if immunotherapy makes its way to the frontline setting, and if patients are all potentially exposed to immunotherapy in the frontline setting, the role of this treatment in subsequent lines of therapy is going to go away. Immunotherapy in the second and subsequent lines of therapy for cholangiocarcinoma is not high on my list for most patients.
CANCER
targetedonc.com

Mitigating Androgen Deprivation Therapy Cardiovascular Risk Factors in nmCRPC

Alicia K. Morgans, MD, PhD, discusses how to handle cardiovascular risk factors associated with androgen deprivation therapy in men with non-metastatic castration-resistant prostate cancer. Alicia K. Morgans, MD, PhD, an associate professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University Feinberg School of Medicine, discusses...
oncnursingnews.com

Prescribing Considerations for Patients with Chronic Leukemia

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, discusses the importance of NCCN guidelines in prescribing medications for patients with chronic leukemia. . In the era of precision medicine, individualized care is tailored to the patient in a way that wasn’t possible 15 or 20...
CANCER
ajmc.com

Palmetto GBA’s MolDX Announces Coverage of MRD Testing

The decision will provide Medicare coverage tests for minimal residual disease (MRD) starting December 26, 2021. In an important advance for precision medicine, the Medicare Administrative Contractor Palmetto GBA, through its Molecular Diagnostics Program (MolDX), has recently finalized a local coverage determination (LCD) for tests for minimal residual disease (MRD)1. Following the release of a draft policy in September 2020, the final LCD in MRD testing was announced November 11, 2021.
HEALTH
urologytimes.com

Patient Case #1: Treatment Selection in mCNPC

Raoul S. Concepcion, MD, FACS: Let’s go to the first case. This is module 1, and we’re going to talk about recent advances in the treatment of metastatic castration-naïve prostate cancer. We’ve generally gone to this type of nomenclature. We should have some standardization. Everybody is very comfortable with castration-resistant prostate cancer. Many of us have used castration sensitive and hormone sensitive. I changed this because I was looking at the 2022 NCCN [National Comprehensive Cancer Network] Guidelines, and they changed their nomenclature to castration naïve.
CANCER
auntminnie.com

Teamwork reduces variability in surveillance mammography

November 19, 2021 -- Collaboration between referring clinicians and radiologists could decrease variability in surveillance imaging for breast cancer survivors, according to a survey study published November 17 in the Journal of the American College of Radiology. A team led by Dr. Derek Nguyen from Johns Hopkins Medicine in Baltimore...
CANCER
onclive.com

Molecular Testing in Metastatic Urothelial Cancer During COVID-19

Arlene O. Siefker-Radtke, MD: Now, the NCCN [National Cancer Comprehensive Network] guidelines advocate for testing for patients with stage IV disease, and they also recommend considering testing for patients with stage IIIB on a more selected basis. The patients I typically recommend testing for in that perioperative space as part of our standard of care strategy would be patients at high risk of recurrence. For instance, a patient who had neoadjuvant chemotherapy and at surgery still had high volume T3b or T4a or greater disease, or lymph node involvement due to their high rate of recurrence. Testing early can help us plan ahead and get patients on clinical trials and prepare them for what might be needed down the road. Are you facing any challenges, Scott, with the COVID-19 pandemic? I know it has been challenging for some patients getting access to care and getting tissue sent for review. Has the pandemic altered your strategy at all?
CANCER
dweb.news

የፊት ገጽ፡ በJNCCN ውስጥ የተደረገ አዲስ ጥናት ቁልፍ የሉኪሚያ መድኃኒት እጦት አስጨናቂ አገኘ።

Newswise — PLYMOUTH MEETING, PA [November 16, 2021] — New research in the November 2021 issue of JNCCN - ጆርናል ኦፍ ብሔራዊ አጠቃላይ የካንሰር አውታረ መረብ finds fewer than one-third of hospitals had immediate availability of a crucial blood cancer medication called all-trans retinoic acid (ATRA). ATRA should be initiated in the early stages of treatment for acute promyelocytic (APL) leukemia. This is a form of acute myeloid (AML), and can prevent major bleeding, clotting, or even death. APL is easily treatable, and has a better prognosis when it is treated properly.
DISEASES & TREATMENTS

NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects

PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) recently announced new funding for projects to improve patient care and outcomes in early-stage non-small cell lung cancer (NSCLC). Funding will be provided through support from AstraZeneca. “This project will help us address gaps and barriers...
CANCER
Newswise

New Study in JNCCN Finds Disturbing Lack of Key Leukemia Medication

Newswise — PLYMOUTH MEETING, PA [November 16, 2021] — New research in the November 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds fewer than one-third of hospitals had immediate availability of a crucial blood cancer medication called all-trans retinoic acid (ATRA). ATRA is initiated early in the treatment of acute promyelocytic leukemia (APL)—a form of acute myeloid leukemia (AML), to prevent major bleeding, clotting, and potential death. APL is very treatable and tends to have a better prognosis than other subtypes of AML when treated appropriately.
CANCER
targetedonc.com

NCCN Update to ALL Guideline Places Greater Emphasis on Philadelphia Chromosome Status

The National Comprehensive Cancer Network has updated its guidelines on ALL in adolescents and young adults. National Comprehensive Cancer Network (NCCN) Guidelines for acute lymphoblastic leukemia (ALL) have been updated to put a greater focus on the differences between the management of Ph-positive and PH-negative ALL in adolescents and young adults.
CANCER
YOU MAY ALSO LIKE